Royalty Report: Drugs, HIV / AIDs, Disease – Collection: 233457


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • HIV / AIDs
  • Disease
  • Therapeutic
  • Immune
  • Vaccine
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233457

License Grant
The Parties now revise certain terms and conditions of the Agreement to give effect to the Parties’ agreement that Swiss Licensee will take over control of Development, Commercialization and Manufacture of the LdT Product and related matters, on a worldwide basis.

With this amendment, the HBV License now reads as follows for the LdT License
– Subject to the terms and conditions of this Agreement,  Licensor grants to The Swiss Licensee a right and license, with the right to grant sublicenses as permitted, under Licensors rights in the Licensors Intellectual Property and in the Joint Intellectual Property to manufacture, have made, use, market and promote, import and export, offer for sale, sell and distribute the LdT Product in the Field within the Licensees Territory during the applicable Country Terms for the LdT Product.   The license granted to Licensee in this subsection shall be exclusive, even with respect to Licensor as to the Licensees Territory.

With this amendment,  EU Countries and Licensee takes over control of Development, Manufacture and Commercialization worldwide, and books sales.
– Licensee will pay royalties for the US Territory, the Major EU Countries and the Rest of World Territory.
– the Parties will terminate the existing Supply Agreement and the Commercial Manufacturing Agreement, along with some changes to other agreements.
– Licensor grants to Licensee a license to Manufacture worldwide.

This agreement has pediatric exclusivity terms and a non-exclusive grant back to Licensor.

License Property
LdT Product Patent Rights means those Licensor LdT Product Patent Rights, where Licensor is the patent owner, co-owner or licensee, including for the avoidance of doubt, pediatric exclusivity terms.

The patents cover
– Methods of Treating Hepatitis Delta Virus Infection with Beta-L-2- Deoxynucleosides
– Crystalline and Amorphous Forms of B-L-2-Deoxythymidine
– B-L-2-Deoxynucleosides for the Treatment of Lamivudine-Resistant
– Industrially Scalable Nucleoside Synthesis
– Synthesis of Beta-L-2- Deoxynucleosides
– B-L-2-Deoxypyrimidine Nucleosides for the Treatment of Hepatitis B, and,
– Methods of Manufacture of 2-Deoxy-B-L-Nucleosides

Field of Use
Licensor is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. The Company’s current focus is on diseases caused by hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.

IPSCIO Record ID: 3782

License Grant
A University Research Foundation won, by settlement, an up-front payment and royalties on a drug to treat hepatitis.

The intellectual property was taken from the University and includes possible treatments for herpes, HIV, and other viruses.  The University sued the company who was gaining from the patents, asserting that a former professor had founded the Licensee company and made off with University intellectual property.  The settlement applies to worldwide sales of telbivudine, an antiviral drug used to treat Hepatitis B.

Field of Use
The rights granted apply in the use of LdT for treating Hepatitis B virus infections (HBV infections).

IPSCIO Record ID: 362455

License Grant
The University grants an exclusive, worldwide, right and license under the University Subject Technology to develop, make, have made, use, market, import, have imported, Sell, offer for Sale and have Sold any and all Licensed Products in the field and in the Territory.
License Property
The University owns certain intellectual property relating to the treatment of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).

Licensed Products means a product containing P-VL-FD4C that is developed, made, used, marketed, imported, Sold, or offered for Sale by Licensee, its Affiliates or any Sublicensees in any country of the Territory where the University owns or controls at least one Valid Claim covering the Subject Technology.

University Subject Technology shall mean all technology, trade secrets, know-how, methods of treatment, documents, materials, tests, all improvements thereto, and all proprietary information pertaining to the compound B-L-FD4C (2 ,3-dideoxy-2 ,3 -didehydro-B-L-5-fluorocytidine) or any 5- or N4 derivatives or products thereof.

Field of Use
Field means all human prophylactic and therapeutic applications with respect to HIV and HBV.

IPSCIO Record ID: 362454

License Grant
Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property
The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use
The field of use includes HIV treatments.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.